{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:12:27Z","timestamp":1791637947730,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Esaxerenone, which blocks aldosterone binding, is approved to treat hypertension but not heart failure. We aimed to understand esaxerenone\u2019s efficacy in treating chronic heart failure. This crossover study compared esaxerenone with eplerenone, an approved treatment for heart failure, in 66 patients with chronic heart failure complicated by hypertension (12 months for each drug). The primary endpoint was brain natriuretic peptide. The secondary endpoints included blood pressure; hormones and enzymes that regulate electrolytes and stress response; and biomarkers of kidney function. Change in brain natriuretic peptide concentration was significantly lower for esaxerenone compared with eplerenone at 3, 6, and 12 months. Blood pressure (all time points), plasma aldosterone concentration (3 and 6 months), and urinary albumin-to-creatinine ratio (3 and 6 months) were significantly lower for esaxerenone compared with eplerenone. The results suggest that esaxerenone more strongly blocks aldosterone binding than does eplerenone. This effect, together with its strong antihypertensive effect and reduced urinary albumin-to-creatinine ratio, suggests that esaxerenone improves kidney function. The results of this small-scale, single-center study need to be expanded to a larger-scale investigation, but esaxerenone shows promise as a treatment for chronic heart failure with hypertension.<\/jats:p>","DOI":"10.3390\/life15050741","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:31:36Z","timestamp":1746419496000},"page":"741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-9082","authenticated-orcid":false,"given":"Akira","family":"Sezai","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5415","authenticated-orcid":false,"given":"Msasnori","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension, and Endocrinology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension, and Endocrinology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Taoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakuni","family":"Sekino","sequence":"additional","affiliation":[{"name":"Sekino Hospital, 3-28-3, Ikebukuro, Toshima-ku, Tokyo 171-0014, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ejhf.3454","article-title":"Efficacy and safety of angiotensin receptor\u2013neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis","volume":"27","author":"Nguyen","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.33963\/v.phj.100199","article-title":"Effects of SGLT2 inhibitors on right ventricular function in heart failure patients: Updated meta-analysis of the current literature","volume":"82","author":"Cinar","year":"2024","journal-title":"Kardiol. Pol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10157-018-1567-1","article-title":"Independent regulation of renin\u2013angiotensin\u2013aldosterone system in the kidney","volume":"22","author":"Nishiyama","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: The fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Bauersachs","year":"2007","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ajh\/hpaa155","article-title":"Effect of the nonsteroidal mineralocorticoid receptor blocker, esaxerenone, on nocturnal hypertension: A post hoc analysis of the ESAX-HTN study","volume":"34","author":"Kario","year":"2021","journal-title":"Am. J. Hypertens."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5761\/atcs.oa.11.01691","article-title":"Effects of olmesartan on the renin\u2013angiotensin\u2013aldosterone system for patients with essential hypertension after cardiac surgery\u2014Investigation using a candesartan change-over study","volume":"17","author":"Sezai","year":"2011","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5761\/atcs.oa.16-00054","article-title":"Changeover trial of azilsartan and olmesartan comparing effects on the renin\u2013angiotensin\u2013aldosterone system in patients with essential hypertension after cardiac surgery (CHAOS Study)","volume":"22","author":"Sezai","year":"2016","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qiang, P., Hao, J., Yang, F., Han, Y., Chang, Y., Xian, Y., Xiong, Y., Gao, X., Liang, L., and Shimosawa, T. (2022). Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor\/TGF-\u03b21 pathway in mice induced with aldosterone. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.948658"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41440-022-01008-w","article-title":"The renoprotective effect of esaxerenone independent of blood pressure lowering: A post hoc mediation analysis of the ESAX-DN trial","volume":"46","author":"Okuda","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","article-title":"Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: A multicenter, single-arm, open-label phase III study","volume":"25","author":"Ito","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/s41440-019-0320-9","article-title":"Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?","volume":"42","author":"Sato","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","article-title":"Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction","volume":"44","author":"Ito","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","article-title":"Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: A single-arm, open-label study","volume":"42","author":"Itoh","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41440-021-00756-5","article-title":"Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","article-title":"Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF)","volume":"82","author":"Tsutsui","year":"2018","journal-title":"Circ. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0003-4975(99)01305-3","article-title":"Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery","volume":"69","author":"Sezai","year":"2000","journal-title":"Ann. Thorac. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2009.11.085","article-title":"Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose Human ANP Infusion Therapy during Cardiac Surgery) for left ventricular dysfunction","volume":"55","author":"Sezai","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jacc.2011.03.056","article-title":"Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose HANP Infusion Therapy during Cardiac Surgery) trial for CKD","volume":"58","author":"Sezai","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"The RALES Investigators (1996). Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol., 78, 902\u2013907.","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s12325-022-02282-3","article-title":"Antihypertensive effect of long-term monotherapy with esaxerenone in patients with essential hypertension: Relationship between baseline urinary sodium excretion and its antihypertensive effect","volume":"39","author":"Ichikawa","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1470320310390404","article-title":"Efficacy of eplerenone added to renin\u2013angiotensin blockade in elderly hypertensive patients: The Jichi Eplerenone Treatment (JET) study","volume":"12","author":"Yano","year":"2011","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1253\/circrep.CR-21-0115","article-title":"Implication of mineralocorticoid receptor antagonist esaxerenone in patients with heart failure with preserved ejection fraction","volume":"3","author":"Imamura","year":"2021","journal-title":"Circ. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41440-020-00606-w","article-title":"Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure","volume":"44","author":"Naruke","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis","volume":"33","author":"Berry","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","article-title":"Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)","volume":"73","author":"Hamaguchi","year":"2009","journal-title":"Circ. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction\u2014A report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: An individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:27:10Z","timestamp":1760030830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["life15050741"],"URL":"https:\/\/doi.org\/10.3390\/life15050741","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}